Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics' stock price has experienced significant volatility over the past six months, decreasing by 61.97% over the last 12 months. Pfizer's termination of their partnership for the hemophilia A gene therapy program in late 2024 significantly impacted the stock. Recent positive developments include the FDA's acceptance of Sangamo's request for a rolling Biologics License Application (BLA) submission for ST-920 in Fabry disease in November 2025, and the initiation of this rolling submission in December 2025. Additionally, ST-503 for small fiber neuropathy received U.S. FDA Fast Track Designation in December 2025.

The demand for Sangamo Therapeutics' products and services does not typically exhibit traditional consumer-driven seasonality. Instead, demand is largely influenced by clinical trial outcomes, regulatory approvals, and the progression of its pipeline. Positive clinical trial results or regulatory milestones can generate significant interest and potential future demand for its therapies, while setbacks can negatively impact perceived demand and investor confidence.

Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on genomic medicine, utilizing cell and gene therapy to address genetic diseases. The company's proprietary zinc finger technology is central to its research across gene therapy, gene editing, cell therapy, and gene regulation. Sangamo's major product candidates and programs target a range of serious conditions, including Isaralgagene civaparvovec (isa-vec, ST-920) for Fabry disease, SB-525 for Hemophilia A, SAR445136 for sickle cell disease, ST-503 for intractable pain due to idiopathic small fiber neuropathy (iSFN), and TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation. Sangamo also engages in various partnerships and collaborations with leading global pharmaceutical companies.

Sangamo Therapeutics, Inc. is headquartered in Brisbane, California, United States, and maintains offices in Richmond, California, the United Kingdom, and France.

Sangamo Therapeutics has been at a "critical juncture," navigating financial challenges despite a promising pipeline. The termination of the partnership with Pfizer significantly impacted the company's standing and likely its brand reputation. Positive clinical data from its Fabry disease program (ST-920) and the Fast Track Designation for ST-503 for small fiber neuropathy contribute positively to its reputation.

Sangamo Therapeutics, Inc. has a diverse ownership structure. As of early 2026, institutional shareholders own 18.60% of the company, individual insiders own 9.54%, and retail investors hold 71.85%. Major institutional owners include Vanguard Group Inc, Renaissance Technologies Llc, BlackRock, Inc., Gsa Capital Partners Llp, Geode Capital Management, Llc, Two Sigma Investments, Lp, Susquehanna International Group, Llp, and Biogen Inc.